{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:04:12Z","timestamp":1781247852295,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00417-025-06736-6","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T13:01:15Z","timestamp":1736859675000},"page":"965-972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vitritis following intravitreal faricimab: a retrospective monocentric analysis"],"prefix":"10.1007","volume":"263","author":[{"given":"Alexandre","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-4379","authenticated-orcid":false,"given":"Salomon Yves","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Nghiem-Buffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Smadja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Paques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Fajnkuchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mrejen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"6736_CR1","doi-asserted-by":"publisher","unstructured":"Saharinen P, Eklund L, Alitalo K (2017) Therapeutic targeting of the angiopoietin\u2013TIE pathway. Nat Rev Drug Discov 16:635\u2013661. https:\/\/doi.org\/10.1038\/nrd.2017.101","DOI":"10.1038\/nrd.2017.101"},{"key":"6736_CR2","unstructured":"FDA Approves Genentech\u2019s Vabysmo [cited 2024 May 19]. Available from: https:\/\/www.gene.com\/media\/press-releases\/14943\/2022-01-28\/fda-approves-genentechs-vabysmo-the-firs. Accessed 15 Dec 2024"},{"key":"6736_CR3","unstructured":"EMA Vabysmo presentation [cited 2024 May 19]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vabysmo"},{"key":"6736_CR4","unstructured":"Arr\u00eat\u00e9 du 10 octobre 2023 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. [cited 2024 May 19]. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000048219057"},{"key":"6736_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00006-9","volume":"399","author":"CC Wykoff","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 399:741\u2013755. https:\/\/doi.org\/10.1016\/S0140-6736(22)00006-9","journal-title":"Lancet"},{"key":"6736_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-0","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-0","journal-title":"Lancet"},{"issue":"8","key":"6736_CR7","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.016","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related Macular degeneration trials of Faricimab with treat-and-extend dosing in year 2. Ophthalmol 131(8):914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.016","journal-title":"Ophthalmol"},{"key":"6736_CR8","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41598-024-52492-0","volume":"14","author":"WT Yen","year":"2024","unstructured":"Yen WT, Wu CS, Yang CH et al (2024) Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis. Sci Rep 14:2485. https:\/\/doi.org\/10.1038\/s41598-024-52492-0","journal-title":"Sci Rep"},{"key":"6736_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0325","volume":"142","author":"L Thangamathesvaran","year":"2024","unstructured":"Thangamathesvaran L, Kong J, Bressler SB et al (2024) Severe intraocular inflammation following Intravitreal Faricimab. JAMA Ophthalmol 142:365. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.0325","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"6736_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.003","volume":"9","author":"SY Sim","year":"2024","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G et al (2024) Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to Faricimab. Ophthalmol Retina 9(1):22\u201330. https:\/\/doi.org\/10.1016\/j.oret.2024.07.003","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"6736_CR11","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","volume":"142","author":"M Cozzi","year":"2024","unstructured":"Cozzi M, Ziegler A, Fasler K et al (2024) Sterile intraocular inflammation Associated with Faricimab. JAMA Ophthalmol 142(11):1028\u20131036. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.3828","journal-title":"JAMA Ophthalmol"},{"key":"6736_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","volume":"269","author":"I Ben Ghezala","year":"2024","unstructured":"Ben Ghezala I, Gabrielle P, Sibert M (2024) Severe intraocular inflammation after Intravitreal Injection of Faricimab: a single-site Case Series of six patients. Am J Ophthalmol 269:11\u201319. https:\/\/doi.org\/10.1016\/j.ajo.2024.08.008","journal-title":"Am J Ophthalmol"},{"key":"6736_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/IAE.0000000000000811","volume":"36","author":"PD Williams","year":"2016","unstructured":"Williams PD, Chong D, Fuller T, Callanan D (2016) Noninfectious vitritis after intravitreal injection of anti-VEGF agents: variations in rates and presentation by medication. Retina 36:909\u2013913. https:\/\/doi.org\/10.1097\/IAE.0000000000000811","journal-title":"Retina"},{"key":"6736_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4274\/tjo.galenos.2021.49540","volume":"51","author":"M Kaya","year":"2021","unstructured":"Kaya M, \u00d6ner FH, Akbulut Ya\u011fc\u0131 B et al (2021) Non-infectious intraocular inflammation following intravitreal anti-vascular endothelial growth factor injection. Turk J Ophthalmol 51:32\u201337. https:\/\/doi.org\/10.4274\/tjo.galenos.2021.49540","journal-title":"Turk J Ophthalmol"},{"key":"6736_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oret.2019.05.004","volume":"3","author":"JP Greenberg","year":"2019","unstructured":"Greenberg JP, Belin P, Butler J et al (2019) Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina 3:753\u2013759. https:\/\/doi.org\/10.1016\/j.oret.2019.05.004","journal-title":"Ophthalmol Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06736-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T03:02:49Z","timestamp":1747796569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06736-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6736"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06736-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Independent Review Board\/Ethics Committee of the Federation France Macula (approval number: 2024-17).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study approval statement"}},{"value":"Patients gave their informed consent to be treated with intravitreal injections. After the occurrence of intraocular inflammation, they were informed of our intent to report this complication, and they gave their consent for this reporting.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate statement"}},{"value":"S.Y.C. is a consultant for Abbvie, Bayer, Novartis, Roche, and Thea. S.N.-B. and F.F. are consultants for Abbvie, Bayer, and Novartis. S.M. is a consultant for Abbvie, Bayer, Novartis, and Roche. A.B., J.S., and M.P. have no conflicts of interest to disclose. Roche\/Genentech, the manufacturer of faricimab, was not involved in the conduct or design of this study or in the decision to analyze and report the findings.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}